A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts
Background Pleural mesothelioma (PM) is a rare, asbestos-linked cancer with a long asymptomatic latency, delaying diagnosis and limiting treatment options. Identifying blood‐based biomarkers that signal disease before symptoms onset could improve surveillance of at‐risk individuals. Methods In our work, we conducted a prospective proteomic study of pre-diagnostic serum from 21 PM cases (< 5 years before…












